Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...

Dr. Todd Maderis, ND  Exploring immune dysregulation, viral reactivation, mitochondrial impairment, and treatment implications in post-EBV fatigue syndromes ...

Doctors are divided over treatment for a rare disorder, but some living with it say the official advice is misleading.

With barzolvolimab re-treatment, 62% of patients with ColdU and 60% of patients with SD had a complete response at Week 20 in the OLE. These findings are consistent with the complete response rates in ...

Blueprint Medicines, a Sanofi company, today announced AYVAKIT(R) (avapritinib) data showing clinically meaningful outcomes and a w ...

Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients ...

Patients with chronic spontaneous urticaria had positive outcomes weeks after barzolvolimab, according to data presented at ...

Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six ...

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data ...

The NHS doctor stated that people with MCAS often have "lots of other things that can cause heartburn or reflux", such as having Ehlers-Danlos, hypermobility syndrome, or even gastroparesis. He warned ...

People who struggle with heartburn that lasts for hours, and medicine doesn't seem to help, are being urged to ask their doctor to consider a certain medical condition as a possibility. Mast Cell ...

Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and ...